By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Presentation Highlights HyBryte Potential in CTCL In January 2025, Dr. Neal Bhatia presented at two dermatology ...

Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in ...

Axos Financial ( ($AX) ) has issued an announcement. On August 12, 2025, Axos Financial, Inc. announced its investor presentation, highlighting ...

Presenting a late-breaking poster presentation on the RECOVER 12-month OLE trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual ...

RICHMOND, Calif.-- (BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.

Physician engagement and enthusiasm for anito-cel continues to build following these data presentations and as more sites gain experience with anito-cel through iMMagine-3, our earlier-line study.

First Quarter 2025 Financial Highlights Cash Position: Cash and cash equivalents, and short-term investments of $136.5 million as of March 31, 2025, compared with $147.3 million as of December 31 ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

The presentations will cover preclinical activity and safety data for STRO-004, the Company’s novel exatecan Tissue Factor ADC, as well as showcase the unique advantages of Sutro’s XpressCF+ ...

The highlight is an oral presentation that will feature emerging survival plateaus from a study of botensilimab plus balstilimab in 343 evaluable patients with refractory metastatic solid tumors ...

Upcoming oral presentation: "INB-200: Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance ...

Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million Topline results expected in 2Q ...